The company’s intellectual property portfolio now includes two new U.S. patents covering the use of Actimab-A in solid tumors by targeting myeloid-derived suppressor cells, extending protection through 2043. These additions shift the focus from traditional tumor-cell targeting to the surrounding microenvironment. Furthermore, Actinium has secured regulatory progress for its AML treatment protocols, with additional patent activity spanning the U.S., Canada, and Japan. To support the upcoming clinical demand, the company has amended its Investigational New Drug application to incorporate an additional manufacturer, aiming to increase supply flexibility for studies conducted alongside the National Cancer Institute.
Actinium Pharmaceuticals Secures Patent Growth and Listing Extension
Actinium Pharmaceuticals has bolstered its Actimab-A program through a series of new patent acquisitions and expanded manufacturing capabilities. As the company prepares for clinical milestones scheduled through 2027, it also confirmed that the NYSE American has granted a compliance extension, allowing its stock to maintain its current listing.
On the regulatory front, NYSE Regulation has accepted a compliance plan submitted by the company in June. This decision provides Actinium until November 27, 2027, to meet continued listing standards under Section 1009 of the NYSE American Company Guide. While the company remains in a period of remediation regarding specific listing requirements, its common stock will continue to trade under the symbol ATNM as officials monitor the progress of the outlined initiatives.
Comments (0)
No comments yet. Be the first!